Skip to Main Content

It’s hardly unprecedented for one federal agency to encroach on another’s turf. But the latest intra-executive-branch dustup is particularly eyebrow-raising.

This fall, acting FDA Commissioner Janet Woodcock wrote a letter to the U.S. Patent and Trademark Office to share “areas of concern” about patents issued for prescription medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment